Results 281 to 290 of about 47,580 (341)

Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform. [PDF]

Biotechnol Rep (Amst)
Li D, Zheng P, Yao X, Zhang B, Zhang J, Qu Y, Yun S, Li Y, Chen S, Fang J.   +9 more
europepmc   +1 more source

Rebalancing Hemostasis: Fitusiran as a First‐in‐Class RNAi Therapy in Hemophilia A and B

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Fitusiran is a first‐in‐class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor‐independent prophylaxis.
Raza Ur Rehman, Rida Fatima, Aymar Akilimali   +2 more
wiley   +1 more source

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. [PDF]

Clin Cancer Res
Ku G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, Wang Z, Feller L, Girda E, Pan H, Kim S, Deng Y, Deng T, Liu T, Powderly J, Spencer K, Schneider R, Berlin J, Xu CC, Ahlers CM, Liu X, Chung JK, Sabbatini P, Park J, Lim Y, Jeon J, Meng Y, Klempner SJ.   +27 more
europepmc   +1 more source

Patient‐Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross‐Sectional Survey

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Cancer treatment management necessitates comprehensive symptom burden assessment, particularly with therapies like immune checkpoint inhibitors (ICIs), known for unique toxicities. While ICIs show promising outcomes, they also induce immune‐related adverse events (irAEs), posing challenges due to their varied onset ...
Simeng Ren, Jingqi Yang, Hongkun Xu, Jiayue Jin, Shuo Wang, Baojin Han, Wenzheng Zhang, Yutong Lv, Jie Liu   +8 more
wiley   +1 more source

Anti‐PD‐1/PD‐L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Anti‐PD‐1/PD‐L1 immunotherapy has changed the treatment landscape of lung cancer. This new approach provides the ability to revitalize the immune system to specifically target and kill cancer cells, thereby creating a new treatment paradigm for patients with non‐small cell lung cancer (NSCLC).
Md Mohiuddin
wiley   +1 more source

Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30

Léxane Fournier, Paul Arras, Lukas Pekar, Harald Kolmar, Stefan Zielonka, Lars Toleikis, Stefan Becker   +6 more
openalex   +1 more source

Balancing Promise and Peril: Hemophilia Gene Therapy Insights

IUBMB Life, Volume 78, Issue 1, January 2026.
ABSTRACT Hemophilia is an inherited disorder characterized by impaired blood clotting caused by mutations in the genes responsible for producing coagulation factor (F) VIII (hemophilia A, HA) or FIX (hemophilia B, HB). Current treatment primarily relies on replacement therapy, involving frequent and costly infusions of FVIII or FIX concentrates.
Saicharan Akula, Ester Borroni, Alessia Cottonaro, Antonia Follenzi, Simone Merlin   +4 more
wiley   +1 more source

ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade. [PDF]

Cancer Immunol Res
Andersson H, Uddbäck I, Hermodsson T, Celander M, Krishna Shetty A, Ljung L, Nilsson A, Sundstedt A, von Schantz L, Varas LA, Levin M, Säll A, Weilguny D, Jansson K, Fritzell S, Hägerbrand K, Lindstedt M, Ellmark P.   +17 more
europepmc   +1 more source

Remarkable Prolongation of Irreversible APTT and Non‐Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review

Journal of Clinical Laboratory Analysis, Volume 40, Issue 2, January 2026.
Patient with a bladder cancer history presented was diagnosed with Acquired hemophilia A (AHA) according to imaging findings and laboratory tests. The parameters returned to normal after treatment of methylprednisolone and cyclophosphamide. With the recurrence of AHA, the patient was finally confirmed to have liver metastases.
Ke‐Han Zhang, Song‐Song Lu, Pei‐Liang Gao, Xue‐Ying Fu, Gui‐Ying Dong   +4 more
wiley   +1 more source

Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy. [PDF]

J Biol Eng
Miura D, Kato Y, Yasunaga M, Kumagai I, Asano R.   +4 more
europepmc   +1 more source